Clinical trials

  • MONALIZUMAB for Acute myeloid leukemia | Myelodysplastic syndrome | Myelodysplastic/myeloproliferative neoplasm
  • tabelecleucel for Epstein-Barr virus-associated primary immunodeficiency lymphoproliferative disease (PID LPD) | Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (PTLD) | Epstein-Barr virus-associated sarcoma (including leiomyosarcoma) | Epstein-Barr virus-associated CNS post-transplant lymphoproliferative disorder
  • Lenvatinib for Malignant pleural mesothelioma
  • Trastuzumab for Breast cancer|Gastroesophageal adenocarcinoma|ERBB2 (HER2) gene-altered cancers
  • AUTOLOGOUS T-CELLS EX VIVO MODIFIED WITH A LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR SPECIFIC FOR CD1A for T-cell acute lymphoblastic leukemia|T-cell lymphoblastic lymphoma
  • Pembrolizumab for Mismatch repair deficient endometrial cancer|Uterine cancer
  • BAY 3547926 for Hepatocellular carcinoma
  • LY4066434 for Pancreatic ductal adenocarcinoma | Non-small cell lung cancer | Colorectal cancer | Advanced solid tumor | Metastatic solid tumor | KRAS-mutant solid tumor
  • (1-(11C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE for Parkinson's disease | Prodromal Parkinson's disease
  • IMLIFIDASE for ANCA-associated vasculitis|Granulomatosis with polyangiitis|Microscopic polyangiitis|Pulmonary alveolar hemorrhage|Acute respiratory distress syndrome
  • Duvelisib for Nodal T-cell lymphoma with T follicular helper (TFH) phenotype | Angioimmunoblastic T-cell lymphoma (AITL) | Follicular T-cell lymphoma
  • HYDROXYCHLOROQUINE SULFATE for Rheumatoid arthritis